Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dimethyl fumarate - Biogen

Next Previous
Drug Profile

Dimethyl fumarate - Biogen

Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; Tecfidera

Latest Information Update: 08 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase II Psoriasis
  • No development reported Pulmonary arterial hypertension; Rheumatoid arthritis

Most Recent Events

  • 06 Dec 2022 The Enlarged Board of Appeal (the EBA) of the European Patent Office dismisses decision of the Technical Board of Appeal of the EPO Opposition Division to revoke the EP2801355 patent
  • 21 Jul 2022 Biogen terminates a phase III in Multiple sclerosis (In children's, In adolescents, Combination therapy) in Colombia, Jordan, South Korea, Malaysia, Mexico, Saudi Arabia, Taiwan, Thailand, Tunisia, Turkey, Estonia, Hungary and USA (SC, Injection) due to long-term difficulties in fulfilling enrolment commitments(NCT03870763)
  • 21 Jun 2022 Biogen has patent protection related to dimethyl fumarate for treatment of multiple sclerosis in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top